CoChat

TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults)

Abouyannis, Michael, FitzGerald, Richard, Ngama, Mwanajuma, Mwangudzah, Hope, Nyambura, Yvonne K., Ngome, Samson, Riako, Debra, Babu, Lawrence, Lewa, Frida, Else, Laura, Dily Penchala, Sujan, Orindi, Benedict, Mumba, Noni, Kalama, Betty, Ndungu, Francis M., Adetifa, Ifedayo, Khoo, Saye, Lalloo, David G., Casewell, Nicholas R., Hamaluba, Mainga · 2022 · Wellcome Open Research
Cited by 22

The DOI matches its Crossref record.

Abstract

Background: Snakebites affect over 5 million people each year, and over 100,000 per year die as a result. The only available treatment is antivenom, which has many shortcomings including high cost, intravenous administration, and high risk of adverse events. One of the most abundant and harmful components of viper venoms are the zinc-dependent snake venom metalloproteinases (SVMPs). Unithiol is a chelating agent which is routinely used to treat heavy metal poisoning. In vivo experiments in small animal models have demonstrated that unithiol can prevent local tissue damage and death caused by a certain viper species. This phase I clinical trial will assess the safety of ascending doses of unithiol with a view for repurposing for snakebite indication. Methods: This open label, single agent, phase I clinical trial of a repurposed drug has a primary objective to evaluate the safety of escalating doses of unithiol, and a secondary objective to describe its pharmacokinetics. In total, 64 healthy Kenyan volunteers from Kilifi County will be dosed in consecutive groups of eight, with dose escalation decisions dependent on review of safety data by an independent data safety monitoring board. Four groups will receive ascending single oral doses, two will receive multiple oral doses, and two will receive single intravenous doses. Follow-up will be for 6-months and includes full adverse event reporting. Pharmacokinetic analysis will define the Cmax, Tmax, half-life and renal elimination. Conclusions: This clinical trial will assess the safety and tolerability of a promising oral therapeutic in a relevant setting where snakebites are prevalent. Unithiol is likely to be safer than antivenom, is easier to manufacture, has activity against diverse snake species, and can be administered orally, and thus shows promise for repurposing for tropical snakebite. Pan African Clinical Trials Registry: PACTR202103718625048 (3/3/2021)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.12688/wellcomeopenres.17682.1

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 37

  1. A Kasturiratne, 2008, The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths., PLoS Med., 5, e218, 10.1371/journal.pmed.0050218 · DOI · Paper page
  2. J Chippaux, 1998, Snake-bites: appraisal of the global situation., Bull World Health Organ., 76, 515-524
  3. 2015, Snake bite—the neglected tropical disease., Lancet., 386, 1110, 10.1016/S0140-6736(15)00247-0 · DOI
  4. H Reid, 1963, Specific antivenene and prednisone in viper-bite poisoning: Controlled trial., Br Med J., 2, 1378-1380, 10.1136/bmj.2.5369.1378 · DOI
  5. A Habib, 2018, The snakebite problem and antivenom crisis from a health-economic perspective., Toxicon., 150, 115-123, 10.1016/j.toxicon.2018.05.009 · DOI
  6. I Abubakar, 2010, Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria., PLoS Negl Trop Dis., 4, e767, 10.1371/journal.pntd.0000767 · DOI
  7. A Habib, 1997, First Clinical Experiences with a New Ovine Fab Echis ocellatus Snake Bite Antivenom in Nigeria: Randomized Comparative Trial with Institute Pasteur Serum (Ipser) Africa Antivenom., Am J Trop Med Hyg., 56, 291-300, 10.4269/ajtmh.1997.56.291 · DOI · Paper page
  8. D Warrell, 1974, Bites by the saw-scaled or carpet viper (Echis carinatus): trial of two specific antivenoms., Br Med J., 4, 437-440, 10.1136/bmj.4.5942.437 · DOI
  9. D Warrell, 1980, Comparison of Pasteur and Behringwerke antivenoms in envenoming by the carpet viper (Echis carinatus)., Br Med J., 280, 607-609, 10.1136/bmj.280.6214.607 · doi:10.1136/bmj.280.6214.607
  10. M Abouyannis, 2021, Clinical outcomes and outcome measurement tools reported in randomised controlled trials of treatment for snakebite envenoming: A systematic review., PLoS Negl Trop Dis., 15, e0009589, 10.1371/journal.pntd.0009589 · DOI
  11. A Habib, 2015, Snakebite is Under Appreciated: Appraisal of Burden from West Africa., PLoS Negl Trop Dis., 9, e0004088, 10.1371/journal.pntd.0004088 · DOI
  12. P Rojnuckarin, 2006, A randomized, double-blind, placebo-controlled trial of antivenom for local effects of green pit viper bites., Trans R Soc Trop Med Hyg., 100, 879-884, 10.1016/j.trstmh.2005.10.006 · doi:10.1016/j.trstmh.2005.10.006
  13. K Sellahewa, 1995, Efficacy of Antivenom in the Treatment of Severe Local Envenomation by the Hump-Nosed Viper (Hypnale hypnale)., Am J Trop Med Hyg., 53, 260-262, 10.4269/ajtmh.1995.53.260 · doi:10.4269/ajtmh.1995.53.260
  14. H Asita de Silva, 2011, Low-Dose Adrenaline, Promethazine, and Hydrocortisone in the Prevention of Acute Adverse Reactions to Antivenom following Snakebite: A Randomised, Double-Blind, Placebo-Controlled Trial., PLoS Med., 8, e1000435, 10.1371/journal.pmed.1000435 · DOI · Paper page
  15. H Deutsch, 1955, Some proteolytic activities of snake venoms., J Biol Chem., 216, 17-26, 10.1016/S0021-9258(19)52280-3 · doi:10.1016/s0021-9258(19)52280-3
  16. V Philpot, 1956, Inhibition and activation of venom proteases., Biochim Biophys Acta., 21, 524-530, 10.1016/0006-3002(56)90190-1 · DOI
  17. C Goucher, 1964, The chemical modification of necrogenic and proteolytic activities of venom and the use of EDTA to produce Agkistrodon piscivorus, a venom toxoid., Toxicon., 2, 139-147, 10.1016/0041-0101(64)90014-5 · doi:10.1016/0041-0101(64)90014-5
  18. J Bjarnason, 1978, Hemorrhagic toxins from Western diamondback rattlesnake (Crotalus atrox) venom: isolation and characterization of five toxins and the role of zinc in hemorrhagic toxin e., Biochemistry., 17, 3395-3404, 10.1021/bi00609a033 · DOI
  19. A Rucavado, 2000, Inhibition of local hemorrhage and dermonecrosis induced by Bothrops asper snake venom: effectiveness of early in situ administration of the peptidomimetic metalloproteinase inhibitor batimastat and the chelating agent CaNa2EDTA., Am J Trop Med Hyg., 63, 313-319, 10.4269/ajtmh.2000.63.313 · DOI · Paper page
  20. S Ainsworth, 2018, The paraspecific neutralisation of snake venom induced coagulopathy by antivenoms., Commun Biol., 1, 34, 10.1038/s42003-018-0039-1 · DOI
  21. L Albulescu, 2019, Preclinical validation of a repurposed metal chelator as a community-based therapeutic for hemotoxic snakebite., bioRxiv., 717280, 10.1101/717280 · doi:10.1101/717280
  22. J Chisolm, 1992, BAL, EDTA, DMSA and DMPS in the Treatment of Lead Poisoning in Children., J Toxicol Clin Toxicol., 30, 493-504, 10.3109/15563659209017937 · doi:10.3109/15563659209017937
  23. A Van der Linde, 2008, Stevens-Johnson syndrome in a child with chronic mercury exposure and 2,3-dimercaptopropane-1-sulfonate (DMPS) therapy., Clin Toxicol (Phila)., 46, 479-481, 10.1080/15563650701779687 · doi:10.1080/15563650701779687
  24. V Sanotskiĭ, 1967, [On the possibility of intravenous use of unithiol in high doses]., Farmakol Toksikol., 30, 480-482
  25. H Aposhian, 1983, DMSA and DMPS--water soluble antidotes for heavy metal poisoning., Annu Rev Pharmacol Toxicol., 23, 193-215, 10.1146/annurev.pa.23.040183.001205 · DOI · Paper page
  26. K Hurlbut, 1994, Determination and metabolism of dithiol chelating agents. XVI: Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers., J Pharmacol Exp Ther., 268, 662-668
  27. F Planas-Bohne, 1980, Toxicological studies on sodium 2,3-dimercaptopropane-1-sulfonate in the rat., Arzneimittelforschung., 30, 1291-1294
  28. L Szinicz, 1983, Effects of repeated treatment with sodium 2,3-dimercaptopropane-1-sulfonate in beagle dogs., Arzneimittelforschung., 33, 818-821
  29. S Stantschew, 1983, [Determination and elimination of mercury depots in persons exposed to mercury]., Z Gesamte Hyg., 29, 388-390
  30. R Heinrich-Ramm, 2003, Arsenic species excretion after dimercaptopropanesulfonic acid (DMPS) treatment of an acute arsenic trioxide poisoning., Arch Toxicol., 77, 63-68, 10.1007/s00204-002-0413-z · doi:10.1007/s00204-002-0413-z
  31. R Maiorino, 1991, Determination and Metabolism of Dithiol Chelating Agents. XII. Metabolism and Pharmacokinetics of Sodium 2,3-Dimercaptopropane-1-Sulfonate in Humans., J Pharmacol Exp Ther., 259, 808-14
  32. R Maiorino, 1996, Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides., J Pharmacol Exp Ther., 277, 375-384
  33. R Maiorino, 1996, Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. III. Urinary mercury after exposure to mercurous chloride., J Pharmacol Exp Ther., 277, 938-944
  34. J Scott, 2012, Profile: The Kilifi Health and Demographic Surveillance System (KHDSS)., Int J Epidemiol., 41, 650-657, 10.1093/ije/dys062 · DOI · Paper page
  35. G Sällsten, 1994, Clearance half life of mercury in urine after the cessation of long term occupational exposure: influence of a chelating agent (DMPS) on excretion of mercury in urine., Occup Environ Med., 51, 337-342, 10.1136/oem.51.5.337 · doi:10.1136/oem.51.5.337
  36. H Ovaska, 2008, Severe iatrogenic bismuth poisoning with bismuth iodoform paraffin paste treated with DMPS chelation., Clin Toxicol (Phila)., 46, 855-857, 10.1080/15563650801953182 · doi:10.1080/15563650801953182
  37. L Albulescu, 2020, A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite., Nat Commun., 11, 6094, 10.1038/s41467-020-19981-6 · DOI · Paper page

Cited by

See all 22

Metadata

Authors
Abouyannis, M., FitzGerald, R., Ngama, M., Mwangudzah, H., Nyambura, Y. K., Ngome, S., Riako, D., Babu, L., Lewa, F., Else, L., Dily Penchala, S., Orindi, B., Mumba, N., Kalama, B., Ndungu, F. M., Adetifa, I., Khoo, S., Lalloo, D. G., Casewell, N. R., & Hamaluba, M.
Venue
Wellcome Open Research
Published
2022-03-14
Volume
7
Pages
90
ISSN
2398-502X
Cited by
22
References
0
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (tdm)
Funders
  • Cures Within Reach
  • Research England
  • Wellcome (220531)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults). https://app.cochat.ai/papers/10.12688/wellcomeopenres.17682.1
The paper
Abouyannis, M., FitzGerald, R., Ngama, M., Mwangudzah, H., Nyambura, Y. K., Ngome, S., Riako, D., Babu, L., Lewa, F., Else, L., Dily Penchala, S., Orindi, B., Mumba, N., Kalama, B., Ndungu, F. M., Adetifa, I., Khoo, S., Lalloo, D. G., Casewell, N. R., & Hamaluba, M. (2022). TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults). Wellcome Open Research. https://doi.org/10.12688/wellcomeopenres.17682.1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.